{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T10:26:51Z","timestamp":1769164011338,"version":"3.49.0"},"reference-count":38,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2020,3,1]],"date-time":"2020-03-01T00:00:00Z","timestamp":1583020800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,3,1]],"date-time":"2020-03-01T00:00:00Z","timestamp":1583020800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinicaltherapeutics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2020,3]]},"DOI":"10.1016\/j.clinthera.2020.01.010","type":"journal-article","created":{"date-parts":[[2020,2,7]],"date-time":"2020-02-07T08:05:23Z","timestamp":1581062723000},"page":"546-549","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"title":["Amyotrophic Lateral Sclerosis, Neuroinflammation, and Cromolyn"],"prefix":"10.1016","volume":"42","author":[{"given":"Theoharis C.","family":"Theoharides","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Irene","family":"Tsilioni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2020.01.010_bib1","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/S1474-4422(18)30394-6","article-title":"Immune dysregulation in amyotrophic lateral sclerosis: mechanisms and emerging therapies","volume":"18","author":"Beers","year":"2019","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.clinthera.2020.01.010_bib2","doi-asserted-by":"crossref","first-page":"17728","DOI":"10.1038\/s41598-019-53982-w","article-title":"Cromolyn sodium delays disease onset and is neuroprotective in the SOD1(G93A) Mouse Model of amyotrophic lateral sclerosis","volume":"9","author":"Granucci","year":"2019","journal-title":"Sci Rep"},{"key":"10.1016\/j.clinthera.2020.01.010_bib3","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1056\/NEJMra1409760","article-title":"Mast cells, mastocytosis, and related disorders","volume":"373","author":"Theoharides","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clinthera.2020.01.010_bib4","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1016\/j.clinthera.2013.04.002","article-title":"Atopic conditions in search of pathogenesis and therapy","volume":"35","author":"Theoharides","year":"2013","journal-title":"Clin Ther"},{"key":"10.1016\/j.clinthera.2020.01.010_bib5","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1111\/j.1600-0404.1974.tb02806.x","article-title":"Mast cells in plaques of multiple sclerosis","volume":"50","author":"Olsson","year":"1974","journal-title":"Acta Neurol Scand"},{"key":"10.1016\/j.clinthera.2020.01.010_bib6","doi-asserted-by":"crossref","first-page":"3611","DOI":"10.3390\/ijms20153611","article-title":"Mast cells, stress, fear and autism spectrum disorder","volume":"20","author":"Theoharides","year":"2019","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.clinthera.2020.01.010_bib7","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.123249","article-title":"Mast cells and neutrophils mediate peripheral motor pathway degeneration in ALS","volume":"3","author":"Trias","year":"2018","journal-title":"JCI Insight"},{"key":"10.1016\/j.clinthera.2020.01.010_bib8","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1111\/imr.12634","article-title":"Mast cells as sources of cytokines, chemokines, and growth factors","volume":"282","author":"Mukai","year":"2018","journal-title":"Immunol Rev"},{"key":"10.1016\/j.clinthera.2020.01.010_bib9","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1016\/j.iac.2006.05.005","article-title":"Mast cell mediators in allergic inflammation and mastocytosis","volume":"26","author":"Castells","year":"2006","journal-title":"Immunol Allergy Clin North Am"},{"key":"10.1016\/j.clinthera.2020.01.010_bib10","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/S0065-2776(08)00403-3","article-title":"New insights on mast cell activation via the high affinity receptor for IgE","volume":"98","author":"Rivera","year":"2008","journal-title":"Adv Immunol"},{"key":"10.1016\/j.clinthera.2020.01.010_bib11","first-page":"449","article-title":"New concepts in neuroinflammation: mast cells pro-inflammatory and anti-inflammatory cytokine mediators","volume":"32","author":"Caraffa","year":"2018","journal-title":"J\u00a0Biol Regul Homeost Agents"},{"key":"10.1016\/j.clinthera.2020.01.010_bib12","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/j.jaci.2018.01.034","article-title":"Mast cells signal their importance in health and disease","volume":"142","author":"Olivera","year":"2018","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.clinthera.2020.01.010_bib13","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.ejphar.2015.07.017","article-title":"Non-IgE mediated mast cell activation1","volume":"778","author":"Yu","year":"2016","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.clinthera.2020.01.010_bib14","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/j.jaci.2018.09.014","article-title":"Effect of IL-33 on de novo synthesized mediators from human mast cells","volume":"143","author":"Theoharides","year":"2019","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.clinthera.2020.01.010_bib15","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1111\/exd.13288","article-title":"Neuroendocrinology of mast cells: Challenges and controversies","volume":"26","author":"Theoharides","year":"2017","journal-title":"Exp Dermatol"},{"key":"10.1016\/j.clinthera.2020.01.010_bib16","doi-asserted-by":"crossref","first-page":"E4002","DOI":"10.1073\/pnas.1524845114","article-title":"SP and IL-33 together markedly enhance TNF synthesis and secretion from human mast cells mediated by the interaction of their receptors","volume":"114","author":"Taracanova","year":"2017","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.clinthera.2020.01.010_bib17","doi-asserted-by":"crossref","first-page":"4448","DOI":"10.1073\/pnas.1000803107","article-title":"IL-33 augments substance P-induced VEGF secretion from human mast cells and is increased in psoriatic skin","volume":"107","author":"Theoharides","year":"2010","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.clinthera.2020.01.010_bib18","doi-asserted-by":"crossref","first-page":"E9381","DOI":"10.1073\/pnas.1810133115","article-title":"Substance P and IL-33 administered together stimulate a marked secretion of IL-1beta from human mast cells, inhibited by methoxyluteolin","volume":"115","author":"Taracanova","year":"2018","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.clinthera.2020.01.010_bib19","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1016\/j.jaci.2014.07.036","article-title":"Autocrine hemokinin-1 functions as an endogenous adjuvant for IgE-mediated mast cell inflammatory responses","volume":"135","author":"Sumpter","year":"2015","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.clinthera.2020.01.010_bib20","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1111\/j.1600-065X.2007.00519.x","article-title":"Differential release of mast cell mediators and the pathogenesis of inflammation","volume":"217","author":"Theoharides","year":"2007","journal-title":"Immunol Rev"},{"key":"10.1016\/j.clinthera.2020.01.010_bib21","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/j.jaci.2018.01.034","article-title":"Mast cells signal their importance in health and disease","volume":"142","author":"Olivera","year":"2018","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.clinthera.2020.01.010_bib22","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.bbadis.2010.12.014","article-title":"Mast cells and inflammation","volume":"1822","author":"Theoharides","year":"2012","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.clinthera.2020.01.010_bib23","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1016\/0091-6749(90)90067-E","article-title":"Cromolyn sodium in the management of systemic mastocytosis","volume":"85","author":"Horan","year":"1990","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.clinthera.2020.01.010_bib24","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1016\/j.jaci.2014.10.032","article-title":"The novel flavone tetramethoxyluteolin is a potent inhibitor of human mast cells","volume":"135","author":"Weng","year":"2015","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.clinthera.2020.01.010_bib25","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1111\/j.1365-2133.2009.09516.x","article-title":"Topical sodium cromoglicate relieves allergen- and histamine-induced dermal pruritus","volume":"162","author":"Vieira Dos","year":"2010","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.clinthera.2020.01.010_bib26","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1126\/science.6153130","article-title":"Antiallergic drug cromolyn may inhibit histamine secretion by regulating phosphorylation of a mast cell protein","volume":"207","author":"Theoharides","year":"1980","journal-title":"Science"},{"key":"10.1016\/j.clinthera.2020.01.010_bib27","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1124\/jpet.117.240564","article-title":"Methoxyluteolin inhibits neuropeptide-stimulated proinflammatory mediator release via mTOR activation from human mast cells","volume":"361","author":"Patel","year":"2017","journal-title":"J\u00a0Pharmacol Exp Ther"},{"key":"10.1016\/j.clinthera.2020.01.010_bib28","doi-asserted-by":"crossref","first-page":"E7049","DOI":"10.1073\/pnas.1604992113","article-title":"Neurotensin stimulates sortilin and mTOR in human microglia inhibitable by methoxyluteolin, a potential therapeutic target for autism","volume":"113","author":"Patel","year":"2016","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.clinthera.2020.01.010_bib29","doi-asserted-by":"crossref","first-page":"3103","DOI":"10.1096\/fj.11-197194","article-title":"Microglia and mast cells: two tracks on the road to neuroinflammation","volume":"26","author":"Skaper","year":"2012","journal-title":"FASEB J"},{"key":"10.1016\/j.clinthera.2020.01.010_bib30","doi-asserted-by":"crossref","first-page":"1872","DOI":"10.2174\/1568026617666181119154247","article-title":"Tetramethoxyluteolin for the treatment of neurodegenerative diseases","volume":"18","author":"Theoharides","year":"2018","journal-title":"Curr Top Med Chem"},{"key":"10.1016\/j.clinthera.2020.01.010_bib31","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1016\/S0031-6997(24)01472-8","article-title":"The effects of plant flavonoids on mammalian cells: implications for inflammation, heart disease and cancer","volume":"52","author":"Middleton","year":"2000","journal-title":"Pharmacol Rev"},{"key":"10.1016\/j.clinthera.2020.01.010_bib32","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.brainresbull.2015.09.002","article-title":"Luteolin as an anti-inflammatory and neuroprotective agent: a brief review","volume":"119","author":"Nabavi","year":"2015","journal-title":"Brain Res Bull"},{"key":"10.1016\/j.clinthera.2020.01.010_bib33","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.3390\/molecules16021471","article-title":"Flavonoids and the CNS","volume":"6","author":"Jager","year":"2011","journal-title":"Molecules"},{"key":"10.1016\/j.clinthera.2020.01.010_bib34","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1016\/j.tips.2012.08.002","article-title":"Target-based selection of flavonoids for neurodegenerative disorders","volume":"33","author":"Jones","year":"2012","journal-title":"Trends Pharmacol Sci"},{"key":"10.1016\/j.clinthera.2020.01.010_bib35","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1016\/j.bcp.2004.05.012","article-title":"The flavones luteolin and apigenin inhibit in\u00a0vitro antigen-specific proliferation and interferon-gamma production by murine and human autoimmune T cells","volume":"68","author":"Verbeek","year":"2004","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.clinthera.2020.01.010_bib36","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1186\/1742-2094-6-29","article-title":"Luteolin as a therapeutic option for multiple sclerosis","volume":"6","author":"Theoharides","year":"2009","journal-title":"J\u00a0Neuroinflammation"},{"key":"10.1016\/j.clinthera.2020.01.010_bib37","doi-asserted-by":"crossref","first-page":"2687","DOI":"10.1073\/pnas.0913572107","article-title":"A\u00a0selective TrkB agonist with potent neurotrophic activities by 7,8-dihydroxyflavone","volume":"107","author":"Jang","year":"2010","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.clinthera.2020.01.010_bib38","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1111\/bph.12201","article-title":"Identification through high-throughput screening of 4'-methoxyflavone and 3',4'-dimethoxyflavone as novel neuroprotective inhibitors of parthanatos","volume":"169","author":"Fatokun","year":"2013","journal-title":"Br J Pharmacol"}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S014929182030045X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S014929182030045X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T08:51:53Z","timestamp":1758963113000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S014929182030045X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3]]},"references-count":38,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2020,3]]}},"alternative-id":["S014929182030045X"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2020.01.010","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2020,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Amyotrophic Lateral Sclerosis, Neuroinflammation, and Cromolyn","name":"articletitle","label":"Article Title"},{"value":"Clinical Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinthera.2020.01.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}